GWAS Meta-Analysis of Suicide Attempt: Identification of 12 Genome-Wide Significant Loci and Implication of Genetic Risks for Specific Health Factors
- PMID: 37777856
- PMCID: PMC10603363
- DOI: 10.1176/appi.ajp.21121266
GWAS Meta-Analysis of Suicide Attempt: Identification of 12 Genome-Wide Significant Loci and Implication of Genetic Risks for Specific Health Factors
Abstract
Objective: Suicidal behavior is heritable and is a major cause of death worldwide. Two large-scale genome-wide association studies (GWASs) recently discovered and cross-validated genome-wide significant (GWS) loci for suicide attempt (SA). The present study leveraged the genetic cohorts from both studies to conduct the largest GWAS meta-analysis of SA to date. Multi-ancestry and admixture-specific meta-analyses were conducted within groups of significant African, East Asian, and European ancestry admixtures.
Methods: This study comprised 22 cohorts, including 43,871 SA cases and 915,025 ancestry-matched controls. Analytical methods across multi-ancestry and individual ancestry admixtures included inverse variance-weighted fixed-effects meta-analyses, followed by gene, gene-set, tissue-set, and drug-target enrichment, as well as summary-data-based Mendelian randomization with brain expression quantitative trait loci data, phenome-wide genetic correlation, and genetic causal proportion analyses.
Results: Multi-ancestry and European ancestry admixture GWAS meta-analyses identified 12 risk loci at p values <5×10-8. These loci were mostly intergenic and implicated DRD2, SLC6A9, FURIN, NLGN1, SOX5, PDE4B, and CACNG2. The multi-ancestry SNP-based heritability estimate of SA was 5.7% on the liability scale (SE=0.003, p=5.7×10-80). Significant brain tissue gene expression and drug set enrichment were observed. There was shared genetic variation of SA with attention deficit hyperactivity disorder, smoking, and risk tolerance after conditioning SA on both major depressive disorder and posttraumatic stress disorder. Genetic causal proportion analyses implicated shared genetic risk for specific health factors.
Conclusions: This multi-ancestry analysis of suicide attempt identified several loci contributing to risk and establishes significant shared genetic covariation with clinical phenotypes. These findings provide insight into genetic factors associated with suicide attempt across ancestry admixture populations, in veteran and civilian populations, and in attempt versus death.
Keywords: Biological Markers; Depressive Disorders; Genetics; Schizophrenia Spectrum and Other Psychotic Disorders; Self-Harm; Suicide.
Conflict of interest statement
Dr. Campos is an employee of Regeneron Pharmaceuticals and may own stock or stock options. Dr. Kranzler has served as an advisory board member for Clearmind Medicine, Dicerna Pharmaceuticals, Enthion Pharmaceuticals, and Sophrosyne Pharmaceuticals and as a consultant for Sobrera Pharmaceuticals; he has received research funding and medication supplies for an investigator-initiated study from Alkermes; he is a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the past 3 years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics; and he is a holder of U.S. patent 10,900,082 (“Genotype-guided dosing of opioid agonists”). Dr. Andreassen has served as national principal investigator for clinical trials sponsored by BI, Janssen, and MAPS; he has served as a consultant for Cortechs.ai and as a speaker for Janssen, Lundbeck, and Sunovion. Dr. Bulik has received grant support from Lundbeckfonden and royalties from Pearson, and she serves as a stakeholder advisory board member for Equip Health. Dr. Kessler has served as a consultant for Cambridge Health Alliance, Canandaigua VA Medical Center, Holmusk, Partners Healthcare, RallyPoint Networks, and Sage Therapeutics, and he has stock options in Cerebral, Mirah, PYM, Roga Sciences, and Verisense Health. Dr. Mann receives royalties for commercial use of the C-SSRS from the Research Foundation for Mental Hygiene. Dr. Polimanti has received a research grant from Alkermes and is co-editor-in-chief of
Figures


Comment in
-
New Insights Into Suicidal Behavior From Large Multi-Ancestry Genetic Meta-Analysis.Am J Psychiatry. 2023 Oct 1;180(10):705-707. doi: 10.1176/appi.ajp.20230610. Am J Psychiatry. 2023. PMID: 37777855 No abstract available.
References
-
- World Health Organization: Suicide. 2021. https://www.who.int/news-room/fact-sheets/detail/suicide
-
- World Health Organization: Preventing Suicide: A Global Imperative. Geneva, World Health Organization, 2014. https://apps.who.int/iris/rest/bitstreams/585331/retrieve
-
- Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality: National Survey on Drug Use and Health, 2021. https://www.samhsa.gov/data/release/2021-national-survey-drug-use-and-he...
-
- Centers for Disease Control and Prevention: CDC WONDER Online Database. 2023. https://wonder.cdc.gov/
-
- Franklin JC, Ribeiro JD, Fox KR, et al.: Risk factors for suicidal thoughts and behaviors: a meta-analysis of 50 years of research. Psychol Bull 2017; 143:187–232 - PubMed
Publication types
MeSH terms
Grants and funding
- UL1 TR001863/TR/NCATS NIH HHS/United States
- UM1 TR004409/TR/NCATS NIH HHS/United States
- R01 MH121521/MH/NIMH NIH HHS/United States
- R01 MH123489/MH/NIMH NIH HHS/United States
- T32 GM007347/GM/NIGMS NIH HHS/United States
- R01 MH122412/MH/NIMH NIH HHS/United States
- MR/L010305/1/MRC_/Medical Research Council/United Kingdom
- R01 MH116269/MH/NIMH NIH HHS/United States
- R01 MH099134/MH/NIMH NIH HHS/United States
- R01 MH121455/MH/NIMH NIH HHS/United States
- S10 OD018522/OD/NIH HHS/United States
- S10 OD026880/OD/NIH HHS/United States
- I01 CX001729/CX/CSRD VA/United States
- R01 ES032028/ES/NIEHS NIH HHS/United States
- R01 MH123922/MH/NIMH NIH HHS/United States
- K01 MH109765/MH/NIMH NIH HHS/United States
- P30 CA042014/CA/NCI NIH HHS/United States
- R01 MH123619/MH/NIMH NIH HHS/United States